Panel Discussion: Re-Evaluating Lymphodepletion to Improve Patient Access & Limit Therapeutic Side Effects

Time: 9:00 am
day: Conference Day Two P1

Details:

• Consider the need for lymphodepletion on cell therapy to identify opportunities to remove preconditioning from therapies
• Identify characteristics of therapies that avoid lymphodepletion to pinpoint opportunities to broaden their benefits to more therapies
• Examine the impact of lymphodepletion on patient recruitment and accessibility

Speakers:

Christopher Jewell Dr Jewell is the company’s CSO. His expertise in bioengineering, immunology, and nanotechnology span two decades of experience, including as the MPower Professor and Minta Read more

Jim Sesic Jim Sesic, is a seasoned regulatory executive with over 20 years of experience across the pharmaceutical, biotech, and cell and gene therapy sectors. As Head Read more

Fred Aslan Fred Aslan, M.D. brings two decades of leadership in the life sciences industry as an executive, investor, and entrepreneur. Most recently, he served as President Read more